Psoriasis Clinical Trial

A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque Psoriasis

Summary

This is an open-label, multi-center study to evaluate the efficacy and safety of VTAMA (tapinarof) cream, 1% in adults with intertriginous psoriasis

View Full Description

Full Description

This is an open-label study in which participants will be assigned to receive VTAMA (tapinarof) cream, 1% once daily for 12 weeks. Study participants will have a follow-up period of 1 week. The study duration will be up to 17 weeks.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

18 years of age or older, at the time of signing the informed consent
Participants with clinical diagnosis of plaque psoriasis, including lesion(s) in intertriginous area(s) and stable disease in intertriginous areas for at least 3 months prior to the study
An iPGA score of 2 (mild), 3 (moderate), or 4 (severe) at screening and baseline
Female subjects of child bearing potential who are engaging in sexual activity that could lead to pregnancy agree to follow the specified contraceptive guidance throughout the study
Negative pregnancy test at Baseline (Day 1)
Capable of giving written informed consent

Exclusion Criteria:

Diagnosis of a type of psoriasis other than plaque psoriasis
Any sign of infection of any of the psoriatic lesions
Concurrent significant dermatologic or inflammatory condition other than plaque psoriasis that, in the Investigator's opinion, would make it difficult to interpret data or assessments during the study
History of or ongoing serious illness or medical, physical, or psychiatric condition(s) that, in the Investigator's opinion, may interfere with participation in the study and ability to understand and give informed consent
History of sensitivity to the study product, or components thereof or a history of drug or other allergy that, in the opinion of the Investigator or Medical Monitor, contraindicates participation in the study
Previous known participation in a clinical study with tapinarof (previously known as GSK2894512 and WBI-1001); previous or current use of VTAMA® (Tapinarof) Cream 1%
Use of any prohibited medication or procedure within the indicated period before the baseline visit including other investigational product within 30 days or 5 half-lives of the investigational product (whichever is longer)
UV light therapy or prolonged exposure to natural or artificial sources of UV radiation (e.g., phototherapy, tanning beds/booths, or therapeutic sunbathing) within 4 weeks prior to the Baseline

Study is for people with:

Psoriasis

Phase:

Phase 4

Estimated Enrollment:

30

Study ID:

NCT05680740

Recruitment Status:

Active, not recruiting

Sponsor:

Dermavant Sciences, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 7 Locations for this study

See Locations Near You

Dermavant Investigative Site
Fort Smith Arkansas, 72916, United States
Dermavant Investigative Site
Los Angeles California, 90045, United States
Dermavant Investigative Site
Boca Raton Florida, 33431, United States
Dermavant Investigative Site
Margate Florida, 33063, United States
Dermavant Investigative Site
Plainfield Indiana, 46168, United States
Dermavant Investigative Site
Houston Texas, 77004, United States
Dermavant Investigative Site
Webster Texas, 77598, United States

How clear is this clinincal trial information?

Study is for people with:

Psoriasis

Phase:

Phase 4

Estimated Enrollment:

30

Study ID:

NCT05680740

Recruitment Status:

Active, not recruiting

Sponsor:


Dermavant Sciences, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.